Bayer AG BAYN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Bayer, NextRNA Therapeutics to Collaborate on New Class of Tumor Treatment
-
Trending: Bayer Gets Favorable Appeals Court Ruling in Roundup Case
-
Bayer's stock surges after U.S. appeals court strikes down Roundup cancer case
-
Bayer Shares Surge After Appeal Win in Roundup Cancer Suit
-
Bayer's Monsanto wins appeal in Roundup cancer lawsuit
-
Bayer's Monsanto Wins Appeal in Roundup Cancer Suit
-
Bayer Posts Net Loss as Tough Agriculture Market Bites — Update
-
Bayer Posts Net Loss, Dragged by Weaker Crop-Science Performance
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- 4.97
- Price/Sales
- 0.56
- Dividend Yield (Trailing)
- 0.40%
- Dividend Yield (Forward)
- 0.40%
- Total Yield
- 0.40%
Company Profile
Bayer is a German healthcare and agriculture conglomerate. Healthcare provides close to half of the company's sales and includes pharmaceutical drugs as well as vitamins and other consumer healthcare products. The firm also has a crop science business that includes seeds, pesticides, herbicides, and fungicides, which was expanded through the acquisition of Monsanto.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Stock Style Box
- Large Value
- Total Number of Employees
- 96,567
- Website
- https://www.bayer.com
Competitors
Valuation
|
Metric
|
BAYN
|
PFE
|
BMY
|
|---|---|---|---|
Price/Earnings (Normalized) | 4.97 | 20.96 | 7.04 |
Price/Book Value | 0.70 | 1.85 | 6.43 |
Price/Sales | 0.56 | 2.90 | 2.36 |
Price/Cash Flow | 3.93 | 21.18 | 7.24 |
Price/Earnings
BAYN
PFE
BMY
Financial Strength
|
Metric
|
BAYN
|
PFE
|
BMY
|
|---|---|---|---|
Quick Ratio | 0.86 | 0.51 | 0.94 |
Current Ratio | 1.27 | 0.86 | 1.16 |
Interest Coverage | 0.70 | −0.88 | −3.16 |
Quick Ratio
BAYN
PFE
BMY
Profitability
|
Metric
|
BAYN
|
PFE
|
BMY
|
|---|---|---|---|
Return on Assets (Normalized) | 4.94% | 3.50% | 3.04% |
Return on Equity (Normalized) | 16.84% | 8.28% | 11.63% |
Return on Invested Capital (Normalized) | 9.08% | 5.39% | 5.77% |
Return on Assets
BAYN
PFE
BMY
Drug Manufacturers - General Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Eli Lilly and Co
LLY
| Pvmffkxtv | Xfyj | $798.8 Bil | |||
| Johnson & Johnson
JNJ
| Sfyrgrdzz | Yqrh | $385.9 Bil | |||
| AbbVie Inc
ABBV
| Vbskfkcx | Wms | $343.2 Bil | |||
| Merck & Co Inc
MRK
| Qgbyktc | Dlj | $278.2 Bil | |||
| Roche Holding AG ADR
RHHBY
| Ljskdwvs | Dmrx | $244.4 Bil | |||
| AstraZeneca PLC ADR
AZN
| Czkbwtyls | Ybbm | $238.9 Bil | |||
| Novartis AG ADR
NVS
| Sscqtgrd | Sdtl | $232.2 Bil | |||
| Amgen Inc
AMGN
| Ydsgkqmz | Lqs | $171.8 Bil | |||
| Pfizer Inc
PFE
| Hjmkfhzx | Dzb | $162.0 Bil | |||
| Sanofi SA ADR
SNY
| Xxdzqlch | Jykr | $140.7 Bil |
United States